MY197301A - Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers - Google Patents

Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers

Info

Publication number
MY197301A
MY197301A MYPI2019005993A MYPI2019005993A MY197301A MY 197301 A MY197301 A MY 197301A MY PI2019005993 A MYPI2019005993 A MY PI2019005993A MY PI2019005993 A MYPI2019005993 A MY PI2019005993A MY 197301 A MY197301 A MY 197301A
Authority
MY
Malaysia
Prior art keywords
peptides
combination
present
cancers
tumor
Prior art date
Application number
MYPI2019005993A
Inventor
Colette Song
Oliver Schoor
Jens Fritsche
Claudia Wagner
Andrea Mahr
Toni Weinschenk
Harpreet Singh
Julia Leibold
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Priority to MYPI2019005993A priority Critical patent/MY197301A/en
Publication of MY197301A publication Critical patent/MY197301A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor- associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
MYPI2019005993A 2017-07-17 2017-07-17 Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers MY197301A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI2019005993A MY197301A (en) 2017-07-17 2017-07-17 Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2019005993A MY197301A (en) 2017-07-17 2017-07-17 Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers

Publications (1)

Publication Number Publication Date
MY197301A true MY197301A (en) 2023-06-12

Family

ID=87761105

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019005993A MY197301A (en) 2017-07-17 2017-07-17 Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers

Country Status (1)

Country Link
MY (1) MY197301A (en)

Similar Documents

Publication Publication Date Title
MX2022005060A (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers.
PH12018500551A1 (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
PH12018501865A1 (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
PH12018500848A1 (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
PH12018500864A1 (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
MX2018009958A (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers.
MX2018004140A (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers.
MX2018005273A (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers.
SG10201806839PA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
PH12019501377A1 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PH12019502308A1 (en) Peptides and combination thereof for use in the immunotherapy against cancers
MX2021001622A (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors.
PH12019502300A1 (en) Peptides and combination of peptides for use in immunotheraphy against leukemias and other cancers
PH12020500051A1 (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
PH12018502159A1 (en) Immunotheraphy against melanoma and other cancers
MY196837A (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
PH12020551958A1 (en) Peptides for use in immunotherapy against cancers
PH12018500665A1 (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PH12018502108A1 (en) Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
PH12018501639A1 (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
MY197301A (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
MY197794A (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
MY197679A (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers